anti-TREM2 antisense oligonucleotides (Ionis Pharmaceuticals/Washington University in St Louis)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameanti-TREM2 antisense oligonucleotides (Ionis Pharmaceuticals/Washington University in St Louis)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionTriggering receptor expressed on myeloid cells 2 inhibitors
TargetsTriggering receptor expressed on myeloid cells 2
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIonis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A